Orchestra BioMed Inc. (OBIO)
5.30
0.03 (0.57%)
At close: Jan 15, 2025, 9:39 AM
undefined% (undefined)
| Bid | 5.26 |
| Market Cap | 201.29M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.6 |
| PE Ratio (ttm) | -3.31 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 5.51 |
| Volume | 7,658 |
| Avg. Volume (20D) | 96,988 |
| Open | 5.47 |
| Previous Close | 5.27 |
| Day's Range | 5.30 - 5.53 |
| 52-Week Range | 3.96 - 10.06 |
| Beta | undefined |
About OBIO
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collabora...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 4, 2020
Employees 56
Stock Exchange NASDAQ
Ticker Symbol OBIO
Website https://orchestrabiomed.com
Analyst Forecast
According to 5 analyst ratings, the average rating for OBIO stock is "Buy." The 12-month stock price forecast is $14.5, which is an increase of 173.83% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Orchestra BioMed Inc. is scheduled to release its earnings on Mar 26, 2025,
during market hours.
Analysts project revenue of $800.00K, reflecting a 205.34% YoY growth and earnings per share of -0.42, making a 13.51% increase YoY.
Analysts project revenue of $800.00K, reflecting a 205.34% YoY growth and earnings per share of -0.42, making a 13.51% increase YoY.
1 week ago ·
Source
+34.5%
Orchestra BioMed shares are trading higher Barclay...
Unlock content with
Pro Subscription
